Shanghai Changzheng Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1955-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.shczyy.com
HiSCs in the Treatment of Rheumatoid Arthritis
Not Applicable
Not yet recruiting
- Conditions
- Rheumatoid Arthritis (RA)
- Interventions
- Biological: hiSCs
- First Posted Date
- 2025-04-27
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT06947746
- Locations
- 🇨🇳
Shanghai ChangZheng hospital, Shanghai, China
5-MTHF Supplementation for Treatment of Type 1 Diabetes Patients
Not Applicable
Not yet recruiting
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Drug: active folateDrug: Placebo
- First Posted Date
- 2025-04-16
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 34
- Registration Number
- NCT06930144
The Aim of This Study is to Assess the Efficacy and Safety of Chidamide, Regorafenib in Combination With Iparomlimab and Tuvonralimab for the Treatment of Advanced Colorectal Cancer in Third-line Therapy and Subsequent Lines.
Phase 2
Recruiting
- Conditions
- Advanced Colorectal Cancer in the Third-line Treatment and BeyondpMMR/MSS Advanced Colorectal Cancer
- Interventions
- Drug: chidamide, regorafenib, and iparomlimab/tuvonralimab
- First Posted Date
- 2025-04-16
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06930118
- Locations
- 🇨🇳
Department of Medical Oncology, Second Affiliated Hospital of Naval Medical University, Shanghai, China
Clinical Study of Safety and Efficacy of Universal PSMA CAR- T in Refractory CRPC
Phase 1
Recruiting
- Conditions
- Metastatic Prostate CancerCastration-resistant Prostate CancerMetastatic Castration-resistant Prostate Cancer
- Interventions
- Biological: PSMA-UCAR T (BRL-302)
- First Posted Date
- 2025-03-26
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 3
- Registration Number
- NCT06895811
- Locations
- 🇨🇳
Changzheng hospital, Shanghai, Shanghai, China
CapeOX Combined With Bevacizumab Plus Anti-PD1 Antibody as Neoadjuvant Therapy for Locally Recurrent Colorectal Cancer
Phase 2
Recruiting
- Conditions
- Locally Recurrent Colorectal Cancer
- Interventions
- First Posted Date
- 2025-03-18
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT06881537
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, China
Safety and Efficacy Evaluation of Anti IGF-1R Monoclonal Antibody Combined With Anti-PD-1 Monoclonal Antibody in Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
Early Phase 1
Recruiting
- Conditions
- mCRPC
- Interventions
- Drug: anti-IGF-1R mAb (Teprotumumab/IBI311) + anti-PD-1 mAb (Tislelizumab)
- First Posted Date
- 2025-03-10
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 7
- Registration Number
- NCT06866548
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
Efficacy and Safety of LC-Z300-01 in Chinese With Type 2 Diabetes
Phase 2
Not yet recruiting
- Conditions
- DiabetesType 2 Diabetes
- Interventions
- Drug: Low-dose LC-Z300-01 twice daily in blindingDrug: High-dose LC-Z300-01 twice daily in blindingDietary Supplement: Placebo twice daily in blindingDrug: High-dose LCZ300-1 twice daily in open-label
- First Posted Date
- 2025-02-26
- Last Posted Date
- 2025-02-26
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT06847178
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
The Characteristics of Blood Glucose Profile and the Changes of Hormones in PPDM-C Population
Not yet recruiting
- Conditions
- Chronic PancreatitisDiabetes
- First Posted Date
- 2025-02-14
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 2000
- Registration Number
- NCT06826729
Quantitative Assessment of Lumbar Facet Joint Degeneration, A Retrospective Study.
Completed
- Conditions
- Facet Joint Pain; Low Back PainFacet Joints; Degeneration ; Deep Learning ;Artificial IntelligenceFacet Joint Disease
- First Posted Date
- 2025-01-22
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 48
- Registration Number
- NCT06786611
- Locations
- 🇨🇳
Changzheng Hospital, Second Military Medical University, Shanghai, Shanghai, China
UCMSCs Combined With Allogeneic Islet Transplantation for the Treatment of Diabetes
Not Applicable
Recruiting
- Conditions
- Diabetes
- Interventions
- Drug: allogeneic islet
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- Shanghai Changzheng Hospital
- Target Recruit Count
- 16
- Registration Number
- NCT06751199
- Locations
- 🇨🇳
Shanghai Changzheng Hospital, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath